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Abstract
MicroRNAs (miRNAs), single-stranded non-coding RNAs, influence myriad biological processes that can contribute to cancer.
Although tumor-suppressive and oncogenic functions have been characterized for some miRNAs, the majority of
microRNAs have not been investigated for their ability to promote and modulate tumorigenesis. Here, we established that
the miR-191/425 cluster is transcriptionally dependent on the host gene, DALRD3, and that the hormone 17b-estradiol
(estrogen or E2) controls expression of both miR-191/425 and DALRD3. MiR-191/425 locus characterization revealed that the
recruitment of estrogen receptor a (ERa) to the regulatory region of the miR-191/425-DALRD3 unit resulted in the
accumulation of miR-191 and miR-425 and subsequent decrease in DALRD3 expression levels. We demonstrated that miR-
191 protects ERa positive breast cancer cells from hormone starvation-induced apoptosis through the suppression of
tumor-suppressor EGR1. Furthermore, enforced expression of the miR-191/425 cluster in aggressive breast cancer cells
altered global gene expression profiles and enabled us to identify important tumor promoting genes, including SATB1,
CCND2, and FSCN1, as targets of miR-191 and miR-425. Finally, in vitro and in vivo experiments demonstrated that miR-191
and miR-425 reduced proliferation, impaired tumorigenesis and metastasis, and increased expression of epithelial markers
in aggressive breast cancer cells. Our data provide compelling evidence for the transcriptional regulation of the miR-191/
425 cluster and for its context-specific biological determinants in breast cancers. Importantly, we demonstrated that the
miR-191/425 cluster, by reducing the expression of an extensive network of genes, has a fundamental impact on cancer
initiation and progression of breast cancer cells.
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Introduction
MicroRNAs (miRNAs) are a class of evolutionarily conserved
regulatory RNAs that pleiotropically suppress gene expression at
post-transcriptional level [1]. MiRNAs control the expression of
10–30% of the human transcriptome and are crucial regulators of
both physiologic and pathologic processes [2–4]. In cancer, the
spectrum of miRNAs expressed in neoplastic cells differs
dramatically from that found in normal cells and it is now well
established that miRNAs play fundamental roles in essentially all
aspects of tumor biology [5,6].
In breast cancer, divergent miRNA expression between normal
and neoplastic tissues has been demonstrated, as well as differential
miRNA expression among the molecular subtypes of breast
cancer, including luminal A, luminal B, Her2+ and basal-like
[7,8]. MiRNAs have been shown to play an important role in
breast cancer initiation and progression. For example, overex-
pression of miR-21 in breast carcinomas has been shown to target
important tumor-suppressor genes such as PTEN, PDCD4, and
TPM1, and was associated with advanced clinical stage, lymph
node metastasis, and poor patient prognosis [9,10]. MiR-10a was
reported to be overexpressed in about 50% of metastatic breast
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cancer and transcriptionally activated by the pro-metastatic
transcription factor TWIST1 [11]. Reduced expression of miR-
126 and miR-335 in the majority of primary breast tumors from
relapsed patients was reported, and simultaneous loss of miR-126
and miR-335 expression was associated with poor distal metasta-
sis-free survival [12]. Oncogene regulation by miRNAs has also
been reported, including tyrosine kinase receptors HER-2 and
HER-3 by miR-125b and miR-205, respectively [13,14], and the
miR-200 family, known to reduce cell migration and invasiveness
by targeting ZEB transcription factor members, was suppressed in
metastatic breast cancer [15,16].
miRNA regulation by estrogen receptor-alpha (ERa), the most
important prognostic and therapeutic indicator in breast cancer,
has recently been described by us and others [17–20]. Specifically,
the majority of miRNAs upregulated by ERa are key components
of a negative feedback loop that restrict E2 action and thus play a
tumor suppressive role. In this regard, ERa-activation of let-7
family members limits the expression of oncogenes, such as Ras
and c-Myc, and promotes differentiation of cancer cells [18]; ERa-
mediated activation of the miR-17/92 cluster functions as a tumor
suppressing mechanism in breast cancer through the downregu-
lation of cyclin D1 and AIB1 by the miR-17/20/106 family and
the direct suppression of ERa mediated by miR-18 and miR-19
[19]. We and others have described a double-negative feedback
loop involving E2-suppressed microRNAs that target ERa,
specifically miR-206 and miR-221&222, resulting in upregulation
of ERa expression and low miRNA level in luminal A-type breast
cancers [17,21].
Recent works from our group have shown that miR-191 is
highly induced in several human solid tumors including colon,
lung, pancreas, prostate, and stomach cancer [22], as well as acute
lymphocytic leukemia (ALL)-associated hematopoietic malignan-
cies [23]. We have also reported a strong positive correlation
between miR-191 expression and ERa levels in breast tumors [7],
suggesting an oncogenic function for this miR. A role for miR-191
in tumorigenesis is further strengthened by several findings,
including that miR-191 is induced by a dioxin family carcinogen,
the miR is hypomethylated and overexpressed in liver cancer
[24,25], and miR-191 inhibition decreases cell proliferation and
tumor growth of hepatocellular carcinoma cells [24]. Further-
more, miR-191 overexpression promotes cell growth and
suppresses apoptosis of gastric cancer cells [26]. However, in
ovarian and thyroid follicular cancer, miR-191 represses MDM4
or CDK6 expression, respectively, thereby delaying cancer
progression and tumor-related death [27,28]. These contradictory
findings indicate that the precise role for miR-191 in human
neoplasia may be tumor-type specific and not well understood.
In this current study, we report a positive association between
ERa expression and miR-191 and miR-425, two intronic miRNAs
hosted by the putative protein coding gene DALR anticodon
binding domain containing 3 (DALRD3), and further show direct
control of the miR-191/425/DALRD3 transcriptional unit by the
E2/ERa axis. We evaluated that the estrogen dependent
activation of miR-191/425 induces proliferation in part by
targeting the estrogen modulated tumor-suppressor gene, EGR1.
We also demonstrated that, when constitutively expressed in
highly aggressive ERa negative breast cancer cells, the miR-191/
425 cluster reprograms gene expression to impair tumorigenicity
and metastatic potential through the suppression of several
different oncogenic proteins.
Results
miR191/425 cluster is positively correlated with ERa
levels
MiR-191 and miR-425 are highly conserved miRNAs found on
human chromosome 3 within the first intron of DALRD3 (Figure
S1). Given their genomic organization and proximity, we
hypothesized that miR-191 and miR-425 are co-transcribed and
transcriptionally dependent on the host gene DALRD3. We
examined expression of mature miR-191, miR-425, and DALRD3
mRNA in 20 different normal human tissues using qRT-PCR
(Figure S2A). Both miRNAs were detected in all tissues and, their
levels of expression were highly correlated, as shown by scatter plot
analyses, (R2= 0.7351; p,0.001) (Figure S2B). However, only a
partial correlation was observed between the host gene DALRD3
and miR-191 (R2= 0.4058; p,0.001) or miR-425 (R2= 0.2101;
p,0.001) (Figure S2B), suggesting the existence of DALRD3-
independent mechanism of miR-191/425 expression/accumula-
tion in some tissues.
Based on the previous association between miR-191 and ERa
and the miR-191 and miR-425 co-expression results (Figure S2A),
it was of interest to examine ERa positive breast tumors for the
expression of miR-191 and miR-425. qRT-PCR analysis of 44
human breast cancer specimens with different ERa status revealed
that miR-191 and miR-425 expression was higher (p-value,0.01)
in ERa positive than ERa negative tumors (Figure 1A). DALRD3
mRNA also showed a significant positive correlation with the ERa
status (Figure 1A and Figure S3A). Next, to further verify the
positive association between ERa levels and miR-191/425
expression, miRNA in-situ hybridization was performed on an
independent set of 132 human breast cancer specimens. As
anticipated, the majority of ERa positive breast tumors were also
miR-191 (80%) and miR-425 (87%) positive, while only 23% and
15% of ERa negative specimens expressed miR-191 and miR-425,
respectively (Figure 1B and Figure S4A). Furthermore, co-labeling
of miR-191 and miR-425 by miRNA in situ-hybridization on the
same ERa positive breast specimens showed co-localization of the
two microRNAs in the majority of breast tumor cells (Figure S4B).
Finally, a set of 16 different breast cancer cells, clustered by
ERa, progesterone receptor (PR) and HER2 expression was also
analyzed for the expression of miR-191, miR-425 and the host
Author Summary
MicroRNAs are small noncoding RNAs that act as
posttranscriptional repressors of gene expression. A
pivotal role for miRNAs in all the molecular processes
driving initiation and progression of various malignancies,
including breast cancer, has been described. Divergent
miRNA expression between normal and neoplastic breast
tissues has been demonstrated, as well as differential
miRNA expression among the molecular subtypes of
breast cancer. Over half of all breast cancers overexpress
ERa, and several studies have shown that miRNA expres-
sion is controlled by ERa. We assessed the global change in
microRNA expression after estrogen starvation and stim-
ulation in breast cancer cells and identified that miR-191/
425 and the host gene DALRD3 are positively associated to
ERa-positive tumors. We demonstrated that ERa regulates
the miR-191/425 cluster and verified the existence of a
transcriptional network that allows a dual effect of
estrogen on miR-191/425 and their host gene. We show
that estrogen induction of miR-191/425 supports in vitro
and in vivo the estrogen-dependent proliferation of ERa
positive breast cancer cells. On the contrary, miR-191/425
cluster reprograms gene expression to impair tumorige-
nicity and metastatic potential of highly aggressive ERa
negative breast cancer cells.
miR-191/425 Cluster in Breast Cancer
PLOS Genetics | www.plosgenetics.org 2 March 2013 | Volume 9 | Issue 3 | e1003311
gene DALRD3. Expression of both miR-191 and miR-425 was
higher in the ERa positive cell lines, with the exception of MDA-
MB-453 (a non-aggressive ERa negative/androgen receptor
positive breast cancer cell line but with a gene expression profile
that overlaps with ERa positive breast cancer cells [29])
(Figure 1C, 1D). DALRD3 expression correlated with the
expression levels of the mature miRNAs (R2= 0.725 for miR-
191, p,0.01; R2= 0.63 for miR-425, p,0.01) (Figure 1C, 1D and
Figure S2C). Moreover, we assessed the expression levels of the
two different alternative splicing variants of DALRD3 and
confirmed that the two variants are both transcribed and their
expression levels are higher in the ERa positive than ERa negative
breast cancer cells (Figure S3B). Taken together, these data
revealed for the first time that miR-191 and miR-425 are co-
transcribed and preferentially expressed in ERa positive breast
cancer cells and tumors.
Estrogen-dependent duality of miR191/425-DALRD3
transcriptional unit
Recently, various microarray approaches have been used to
identify E2-induced miRNA expression in hormone-dependent
breast cancer cells [17–20]. However, based on the lack of
consensus on E2-regulated changes in miRNA expression [30], we
investigated global changes in endogenous miRNA expression
after E2 stimulation of breast cancer cells using the multiplexed
Taqman microRNAs assay, a highly sensitive technology that
allowed us to detect changes in 754 miRNAs (‘‘miRNome’’) with
the same sensitivity of a Taqman realtime PCR. ERa positive
MCF7 cells were hormone starved for 6 days and then exposed to
10 nM of E2 for 6 h. The miRNome was determined at 2, 4, 6
days of hormone deprivation and 6 h after E2 stimulation
(Figure 2A and Table S1). After 6 days of E2 deprivation,
downregulation of 146 and upregulation of 25 mature miRNAs,
organized in 69 different miRNA genes, were observed (fold
change 1.2, p-value,0.05) (Figure 2A). Of these 69 miRNA genes,
43 genes (85 mature miRNAs) were modulated after 6 h of E2
stimulation (Figure 2A). The miR-191/425 cluster showed a
progressive downregulation during the 6 days of hormone
deprivation (p-value,0.05; fold change miR-191: 2 d: 0.82; 4 d:
0.63; 6 d: 0.45; miR-425: 2 d: 0.81; 4 d: 0.78; 6 d: 0.35) followed
by a significant induction by 6 h of E2 stimulation (p-value,0.05;
fold change miR-191: 1.36; miR-425: 1.12) (Table S1). We
assessed the reliability of the treatment by using qRT-PCR to
evaluate the expression levels of the E2-regulated genes, TFF1/
pS2 and miR-17 after 3, 6, 24, 48 and 72 h of E2 stimulation [19]
(Figure S5A). Both genes showed a strong and stable induction
over time after E2 treatment. Next, we performed qRT-PCR on
miR-191 and miR-425 and both miRNA levels increased after E2
Figure 1. miR-191/425 expression is associated with ERa. (A) Expression of miR-191, miR-425 and DALRD3 mRNA in 44 breast tumor
specimens with different status of estrogen receptor a (20 ER2 and 24 ER+) (p-value,0.001). (B) In-situ hybridization for miR-191 and miR-425 and
scrambled control probe (SCR) on breast cancer tissue array containing 132 cores of breast cancer tissues. Bars are 200 mm and inserts represent
higher magnification (206) of selected areas. (C) Schematic representation of miR-191 and miR-425 location in the first intron of the putative protein
coding gene DALRD3 with its two different isoforms. (D) Heat map representing the status of ERa, progesterone receptor (PR) and HER2, confirmed
by western blot analyses, in a set of 15 breast cancer cell lines (Yellow: positive; Blue: negative). Northern blot analyses depicting miR-191 and miR-
425 expression levels. snRNAU6 levels were used as a loading control. Expression levels of all isoforms of DALRD3 mRNA were determined by Taqman
qRT-PCR. All error bars represent mean s.d.
doi:10.1371/journal.pgen.1003311.g001
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Figure 2. ERa regulates miR-191/425 cluster. (A) Schematic representation of E2 modulated miRNA genes (p-value,0.05 and fold change.1.2)
after 6 days of hormone starvation and 6 h of E2 treatment. Blue (down) and yellow (up) columns represent all miRNA genes regulated after hormone
starvation. (B) Mature miR-191, miR-425 and DALRD3 mRNA levels were determined by qRT-PCR (* p-value,0.05) after E2 treatment (10 nM). (C)
Schematic representation of miR-191/425-DALRD3 transcription unit. Green, red and gray boxes depict CpG islands, miR-191/miR-425, and DALRD3
exons, respectively. Prom1 and prom2 regions are represented as red and orange squares, respectively. The red lines across miR-191/425 locus define
the location of the amplicons that were used for the chromatin immunoprecipitation experiments. For ChIP experiment, MCF7 cells were hormone
starved for 6 days and then treated with E2 (10 nM) for 3 h, 6 h and 24 h. The amount of ChIP-enriched DNA was quantified by quantitative PCR
(qPCR), and the results are shown as relative enrichment to the input. (D) Luciferase assays were performed on prom1 and prom2 in HEK293 cells
24 h after transfection (* p-value,0.001). (E) Luciferase assays for prom1 and prom2 after estrogen stimulation. MCF7 cells were hormone starved for
4 days and then transfected with prom1 and prom2 plasmids. 24 hr post-transfection, cells were treated with E2 (10 nM) and luciferase activity
assessed at the reported time points (* p-value,0.05). Error bars indicate s.d. and p-values were obtained with two-sided Student’s t-test.
doi:10.1371/journal.pgen.1003311.g002
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stimulation although with a different kinetic of induction
compared to miR-17 (Figure 2B). Specifically, after 72 h of E2
treatment, we detected a 2- to 3.5-fold induction of miR-191 and -
425 compared to untreated cells and the presence of a block in
their induction at 24 h after E2 treatment (Figure 2B). Next, we
assessed expression levels of the primary precursor of miR-191 and
miR-425; the induction profile was similar to the mature miRNAs
(Figure S5B). Despite the positive correlation between miR-191/
425 and the host gene DALRD3 in breast cancer cells (Figure 1C,
1D), the expression level of the total DALRD3 mRNA was
decreased of 35% after 72 h of E2 treatment compared to
untreated cells (p-value = 0.053) (Figure 2B). qRT-PCR for the two
different alternative splicing variants of DALRD3 also showed a
repression of both variants after estrogen stimulation (Figure S5C).
Moreover, total DALRD3 mRNA and both variants were also
highly upregulated in hormone-deprived MCF7 cells (Figure
S5D). To further confirm the ability of E2 to modulate miR-191/
425, MCF7 were treated with fulvestrant, an ERa antagonist that
induces ERa protein degradation (Figure S6A). We observed a
consistent reduction in miR-191/425 levels and a constant
increase in DALRD3 levels after fulvestrant treatment (Figure
S6B, S6C). TFF1/pS2 expression was downregulated by hormone
deprivation or fulvestrant treatment (Figure S5D; Figure S6C).
Collectively, the data showed that miR-191/425 levels are
positively regulated by ERa, and the increased levels of miR-
191 and miR-425 after estrogen stimulation are associated with a
reduction in the accumulation of the host gene DALRD3.
ERa directly regulates miR191/425 cluster
Next, we addressed the direct involvement of ERa in the
regulation of miR191/425 cluster by performing chromatin
immunoprecipitation (ChIP) experiments across nine different
regions spanning miR-191/425 cluster and covering a region of
4200 bp (Figure 2C). MCF7 cells were E2 starved for 6 days (0 h)
and then treated with E2 (10 nM) for 3 h, 6 h and 24 h.
Enrichment of ERa after E2 treatment was identified at region 3
and 8 (Figure 2C). Region 3 showed a specific enrichment of ERa
that reached the highest levels after 3–6 h of treatment and started
to decrease at 24 h. Although ERa was also detected at region 8
after 3 h and 24 h of E2 treatment, this enrichment was
considered to be non-specific since it was also detected for the
ERa negative MDA-MB-436 cells (Figure 2C). We also examined
the localization of the non-phosphorylated RNA polymerase II
large subunit (polII) and the acetylation status of the histone H3
(AcH3) after E2 treatment (Figure 2C). Immunoprecipitation
against polII showed the presence of two different areas of
enrichment: region 3, with an E2-dependent recruitment of polII
that decreased over time, and region 7–9 which showed a
progressive reduction in polII recruitment during E2 treatment
(Figure 2C). AcH3 ChIP showed a specific enrichment at region 1,
2 and 8 with a significant increase in H3 acetylation after 6 h of E2
treatment only for region 2 (Figure 2C). Taken together, these
experiments show that ERa is recruited to the miR-191/425
genomic locus, in response to the estrogen stimulation.
Because of the presence of two sites of enrichment of polII and
the presence of two CpG islands located at the 59end of the two
isoforms of DALRD3 (Figure 2C), we hypothesized the existence
of two promoter regions: one responsible for the transcription of
the longest isoform of DALRD3, which includes miR-191 and -
425 and a second responsible only for the transcription of the short
isoform of DALRD3. Computer-assisted analysis (Figure S7A)
identified two distinct predicted regions as possible candidates for
promoters regulating miR-191/425/DALRD3 gene transcription:
3900 bp (prom1) a marginal predicted region, located upstream of
the long isoform of DALRD3 and also involved in the production
of miR-191/425; 6500 bp (prom2) a highly likely predicted region,
associated only to the transcription of the short isoform of
DALRD3 mRNA (Figure S7A). To test the transcriptional activity
of these two elements, both putative promoters (Figure 2D) were
cloned individually in the promoter-less pGL3basic luciferase
vector, and their expression was examined in HEK293 cells. Both
vectors showed an increase in the luciferase activity, and as
expected, the highly likely predicted region prom2 showed the
strongest basal luciferase activity (Figure 2D). Next, we assessed
the E2 responsiveness of the two identified promoter regions. We
first tested the luciferase activity of both plasmids in five breast
cancer cell lines with different ERa expression levels (Figure S7B).
Both promoter elements showed higher levels of activity in the
three ERa positive cell lines (MCF7, T47D, BT-474) compared to
the ERa negative cells (BT-459, MDA-MB-436). Treatment with
E2 for 6 h induced a 3-fold increase in luciferase activity for the
prom1 element (Figure 2E); in contrast, luciferase activity for the
prom2 region was repressed by E2 treatment (Figure 2E).
Furthermore, silencing of ERa by siRNA reduced luciferase
activity of the prom1 reporter vector by approximately 50%
specifically in ERa positive cells, but no effect on prom2 activity
was detected (Figure S7C).
Taken together, these experiments showed that (1) ERa directly
regulated miR-191/425 cluster expression and (2) verified the
existence of two promoter elements involved in the transcription of
the two DALRD3 isoforms, allowing a differential accumulation of
miR-191/425 and DALRD3 upon E2 stimulation.
miR-191 controls EGR1 in ERa-positive breast cancer cells
upon E2 stimulation
To identify the functional role of the E2 mediated-induction of
miR-191 and miR-425 in ERa positive breast cancer cells, both
miRNAs were knocked down in estrogen dependent MCF7 cells in
normal culture condition. A 33% reduction in cell proliferation
rate was observed compared to a control oligonucleotide
(Figure 3A). Indeed, enforced expression of miR-191/-425 in
hormone deprived MCF7 cells, with low levels of endogenous
miR-191/425 (Table S1), induced a 70% increase in cell
proliferation (Figure 3A). To shed more light in the proliferative
effects of miR-191/425 in ERa positive breast cancer cells, flow
cytometric analyses of transiently-transfected cells were performed
and revealed an increased number of cells in G1 and fewer cells in
G2/M following knockdown of either miR-191 or miR-425
compared to control cells (Figure 3B and Figure S8A). Moreover,
enforced expression of miR-191/425 in hormone deprived MCF7
cells protects cells from hormone starvation induced apoptosis
(Figure 3C).
We next evaluated the in vivo effect of miR191/425 knockdown
on tumor growth. Specifically, miR-191/425 were transiently
inhibited in ERa positive MCF7 cells for 48 h and tumor growth
was assessed after subcutaneous transplantation of the transfected
MCF7 cells in nude mouse. A 50% reduction in tumor growth was
observed (Figure 3D) in miR-191/425 knocked-down cells
compared to control cells. Same results were also obtained after
xenotrasplantation of miR-191/425 knocked-down ERa positive
ZR-75-1 cells (Figure S8B).
To uncover the molecular players involved in the proliferative
response of ERa positive breast cancer cells controlled by the E2
mediated activation of miR-191/425, published transcriptomic
data set of E2 induced ERa positive MCF7 and ZR-75-1 cells
were compared with the predicted miR-191/425 target genes
[31,32]. Specifically, the target genes of miR-191 and miR-425
obtained from the prediction program Targetscan v5.2 (Table S2)
miR-191/425 Cluster in Breast Cancer
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were compared with the pool of E2 downregulated genes. 43 and
23 miR-191 targets and 199 and 116 miR-425 targets were found
in the E2 repressed gene lists of MCF7 and ZR-75-1, respectively
(Figure S9A). Only 5 and 18 targets for miR-191 and miR-425
were repressed by estrogen in both cell lines respectively (Figure
S9A). We focus our attention on the early growth response 1
(EGR1), a member of the early growth response (EGR)
transcription factor family that has been implicated in breast
cancer progression and antiestrogen resistance [33–35]. First, the
expression levels of EGR1 were assessed after E2 stimulation in
MCF7 cells. EGR1 expression showed a 50% induction after
30 minutes from the stimulation (Figure S9A) followed by a
Figure 3. miR-191/425 cluster effects in ERa-positive breast cancer cells. (A) MTT assay in MCF7 cells transfected with anti-miR-191/425 and
scrambled (CTR) control oligonucleotide in normal culture condition (+E2) and MCF7 cells transfected with miR-191/425 and scrambled (CTR) control
in hormone starvation for 7days (2E2) (* and ** indicate p-value,0.05 and 0.01, respectively). (B) Cell cycle analyses of MCF7 cells transfected with
anti miR-191/425 and scrambled control (CTR) oligonucleotide in normal culture condition. Cells were harvested 72 h following transfection, fixed,
stained with propidium iodide, and analyzed by flow cytometry; the data are representative of three independent experiments. (C) Cell cycle analyses
of MCF7 cells transfected with miR-191/425 and scrambled control (CTR) oligonucleotide. Briefly, MCF7 cells were hormone deprived for 3 days and
then transfected with miRs and control oligonucleotide. Cells were harvested 48 h following transfection, fixed, stained with propidium iodide, and
analyzed by flow cytometry; the data are representative of three independent experiments. (D) In vivo growth kinetic of MCF7 cells transfected with
anti-miR-191/425 and scrambled control oligonucleotide. Briefly, MCF7 were transfected in 10 cm plates by using 2-O-methyl anti miR-191 and miR-
425 oligonucleotides (100 nM); 48 h after transfection, cells were detached and injected in nude mice previously implanted (two weeks before
injection) with estradiol pellets. p-value was calculated on one experiment performed with 6 mice for each group. (E) Levels of EGR1 and p21 were
measured by western blot analyses 72 h after transfection of anti-miR-191, anti-miR-425 and scrambled oligonucleotide control in MCF7 cells.
Densitometric values are reported in red below each band and represent the average of three independent experiments. GAPDH was used as a
loading control. (F) Schematic representation of miR191 binding site located in the 39UTR (in green) of the target gene EGR1. The blue line defines the
39UTR fragment cloned into pGL3 control plasmid and the arrow head indicates the position of the miRNA binding site, whose sequence is reported
below with the mutagenesis strategy used to generate the disruption between miRNA and mRNA of the target gene. Luciferase assays for wildtype
and disrupted miRNA binding sites: (top panel) reduced luciferase activity after miR-191 overexpression; (lower panel) increased luciferase activity
after miR191 enforced expression on mutated plasmid. In the lower panel, luciferase activity values for wildtype and mutated plasmids are
represented as a ratio between the relative luciferase activity of miR-transfected cells with the relative luciferase activity of control-transfected cells. *
represent p-value,0.01. (G) Western blot for EGR1 protein after estrogen treatment of miR-191 knocked-down MCF7 cells. Briefly, MCF7 cells were
hormone deprived for 2 days and then transfected by using 2-O-methyl anti miR-191 (100 nM); 48 h after transfection cell were stimulated with E2
(10 nM) and collected at the reported time points. Densitometric values are reported in red below each band and represent the average of three
independent experiments. GAPDH was used as a loading control. (H) qRT-PCR for EGR1 and p21 mRNAs after miR-191 inhibition in E2 stimulated
MCF7 cells. Gene expression levels are reported as relative expression to GAPDH levels. Error bars indicate s.d. *, ** represent p-value of 0.05 and 0.01,
respectively.
doi:10.1371/journal.pgen.1003311.g003
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continuous repression (Figure S9B). To verify that miR-191
regulates the expression of EGR1, knockdown of miR-191 was
performed in MCF7 cells and western blot analyses confirmed the
upmodulation of EGR1 and its direct transcriptional target
CDKN1A (p21) (Figure 3E) [34]. Next, to assess that miR-191
directly controls EGR1 in cells, a luciferase reporter assay was
performed with a luciferase expressing plasmid containing the
conserved miR-191 predicted binding site for EGR1 cloned after
the luciferase reporter gene (Figure 3F). Co-transfection of miR-
191 with the reporter plasmid significantly suppressed (p-
value,0.01) the luciferase activity of the reporter, relative to
transfection of the control oligonucleotide (Figure 3F). Disruption
of the predicted binding site reduced the inhibitory activity of
miR-191 overexpression on the luciferase activity (Figure 3F). To
study in more depth the interaction miR-191/EGR1, hormone
deprived MCF7 cells were transfected with miR-191 inhibitor and
control oligonucleotide and 48 h later treated with estradiol.
Western blot analyses showed that miR-191 inhibition prevents
EGR1 degradation at 6 h and 24 h after E2 treatment compared
to control cells (Figure 3G). qRT-PCR showed that EGR1 mRNA
is also under the control of miR-191 but only in the early phase of
E2 induction (Figure 3H). As expected, induction of p21 transcript
was confirmed by qRT-PCR specifically in miR-191 knocked-
down (Figure 3H). MiR-191 inhibition was also confirmed by
qRT-PCR (Figure S9C). Taken together, these results highlight
the proliferative effects of E2-induced miR-191/425 cluster in
ERa positive breast cancer cells that are in part related to the
miR-191 repression of the tumor-suppressor gene EGR1.
miR191/425 cluster modifies gene expression in highly
aggressive breast cancer cells
Approximately 75% of diagnosed breast tumors express ERa,
and this ERa-positive status is associated with a better prognosis
and response to hormonal treatment [36]. Several studies
suggested that a fraction of ER-negative tumors arise from ER-
positive precursors [37]. Moreover, restoration of functional ERa
expression in ERa-negative human breast cancer cells can block
their proliferation and aggressiveness, supporting the notion that
ERa confers a less aggressive phenotype of breast cancer [38,39].
To determine if miR-191/425 cluster as a part of the ERa
signaling can partially mediate the anti-proliferative effect that
ERa showed in the aggressive breast cancer cells, a genome-wide
expression analysis in aggressive MDA-MB-231 cells, which
express low levels of miR-191/425, was performed 72 h after
enforcing expression of both miR-191 and miR-425 and control
oligonucleotide (Figure 4A). Unsupervised clustering analyses
showed significant deregulation of gene expression by miR-191/
425, with 753 upregulated and 1105 downmodulated genes
(by.1.5 fold; p-value 0.001) (Table S2). Functional profiling of
these genes defined that the greatest proportion of them is
associated with cell adhesion, adherens junction followed by
phosphatidylinositol signaling (Figure 4B). We used qRT-PCR to
validate the modulation of over 20 genes identified in the
microarray analyses or to their related molecular pathways in
two different breast cancer cell lines (Figure 4C). Expression of
many genes involved in promoting growth and metastasis of breast
cancer cells was found to be downmodulated by miR-191/425
cluster: CCND1, CCND2, E2F1, CSDA and API5, regulatory
proteins of the cell cycle progression and apoptosis [40–42];
FSCN1, TNC, VEGFA, CDC42 and SOX4, which have roles in
angiogenesis and migration, and are involved in filopodia/
invadopodia formation [43–48]; the protooncogene MYC, which
initiates the transcription of a large set of genes involved in cell
growth by stimulating metabolism and protein synthesis [49]; and
SATB1, which reprograms gene expression to enhance aggressive
histomorphological features and invasive capabilities [50]. We also
found that miR-191/425 cluster represses cell-structure and
adhesion genes typical of invasive breast cancer cells such as
fibronectin, an ECM adhesive glycoprotein, and vimentin, the
intermediate filament protein of mesenchymal cells, which
together provide cellular integrity and resistance against stress
[51]. Finally, miR-191/425 cluster upregulates zonula occludens-1
(ZO-1), a component of the tight junction barrier in epithelial and
endothelial cells [52]; E-cadherin (CDH1), an important marker of
epithelial tumor progression; and b-catenin (CTNN1) a compo-
nent of wnt pathway that drives progression in various cancers
[53].
To confirm that targets of the mir-191/425 cluster showed an
enrichment signature in this dataset, we assessed the cumulative
density function (cdf) plot comparing the expression changes of
mir-191 and miR-425 targets based on TargetScan v5.1 gene list
[54]. We found that the mir-191/425 targets set (targets) was more
repressed than the control set of genes (control) matched for
39UTR length, dinucleotide composition, and expression level
(Figure 5A). Stronger repression was observed for the conserved
miR-191/425 cluster targets (conserved targets), suggesting further
enrichment of genuine targets in this set (Figure 5A). These
observations supported the utility of this expression data for the
discovery of novel miRNA targets based on miR-associated genes.
Because the expression levels of target mRNAs tend to correlate
negatively with the expression levels of their specific miRNAs [55],
we next focused on the miR-191/425 downregulated genes. First,
the target prediction program TargetScanv5.1 was used to search
for predicted target genes of miR-191 and miR-425 in the pool of
downregulated genes in miR-191/425-expressing MDA-MB-231
cells (Table S2). This list of genes was further compared with the
list of target genes downregulated exclusively by the expression of
miR-191 or miR-425 (Figure S10 and Table S2). A total of 37 and
346 downregulated targets were obtained for miR-191 and miR-
425, respectively (Figure 5B). Among these large set of genes, we
selected 12 genes (SATB1, CCND2, CTDSP2, SOX4, LRRC8A,
SLC16A2, CSDA for miR-191 and FSCN1, TNC, SIAH2,
CCND1, CSDA for miR-425) predicted to have at least one
potential binding site for miR-191 and/or mir-425 in their
39UTRs. Based on their reduction in miR-191/425-expressing
cells (Figure 4C and Table S2), we tested whether these genes are
direct targets of miR-191 and miR-425 constructing reporter
plasmids containing the miRNA binding site in the 39UTR of
these genes downstream of a luciferase reporter gene (Figure S11A).
Co-transfection experiments showed that the introduction of either
miR-191 or miR-425 markedly suppressed the expression of a
luciferase containing the 39UTR of these downregulated genes
(Figure 5C) but did not affect the luciferase activity of the 39UTR-
CCND1 plasmid, indicating that CCND1 is not a direct target of
miR-425 (data not show). Mutations that disrupt base paring with
miR-191 and miR-425 rescued the luciferase expression for all the
target genes, further confirming that these genes are direct targets
of miR-191 and miR-425 (Figure S11B).
We next focused our attention exclusively on SATB1, CCND2
and FSCN1 as mediators of miR-191 and miR-425 effects,
respectively, because of their strong repression obtained after
miRNA expression and their reported tumorigenic function in
breast cancer [46,50,56,57]. Western blot analyses on MDA-MB-
231 expressing either miR-191 or miR-425 showed a strong
suppression of SATB1 only after enforced miR-191 expression
(Figure 5D). Because of SATB1 repression, we also detected
marked repression of fibronectin and to lesser extent of vimentin
(Figure 5D). Further, we also observed a ,2 fold increase of the b-
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catenin protein (Figure 5D) and its sequestration at the cytoplas-
mic membrane due to the increased expression of e-cadherin
(Figure 5D, 5E). Indeed, miR-191 over-expressing cells also
showed a specific repression of CCND2 as well as CDK6
(Figure 5D), a previously demonstrated miR-191 target [28].
Furthermore, we observed a decrease in the levels of CCND1,
Figure 4. miR-191/425 cluster alters gene expression profile of highly aggressive MDA-MB-231. (A, B) Unsupervised clustering of genes
differentially expressed between miR-191/425 and scrambled oligonucleotide control transfected MDA-MB-231 cells. (C) qRT-PCR for the miR-191 and
miR-425 modulated genes in two different aggressive breast cancer cells after miR-191/425 over-expression. Gene expression levels are reported as
relative expression to GAPDH levels. All graphs showed p-values,0.05 obtained with two-sided Student’s t-test. Error bars indicate s.d.
doi:10.1371/journal.pgen.1003311.g004
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Figure 5. miR191/425 targets identification. (A) Cumulative distribution functions (cdfs) of log2 fold change of mRNA expression between miR-
191/425 and scrambled control cells is plotted. Plots include conserved (pink), predicted miR-191/425 targets (blue line), and control mRNAs (grey
line). Targets include ,2600 predicted TargetScan v5.1 targets of miR-191 and miR-425. Conserved targets contain the ,150 genes ranked by
TargetScan v5.1 branch length scores. The control mRNA set was selected to match the predicted targets in expression, 39UTR length and
composition. p-value 0 2.2e216 by rank sum test. (B) Intersection of predicted miR-191, miR-425 human targets and miR-191/425, miR-191, miR-425
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E2F1 and a strong upmodulation of CDKN1A (p21) for both
miR-191 and miR-425 (Figure 5D). In contrast, miR-425 over-
expression specifically reduced expression of FSCN1, TNC and
CDC42 (Figure 5D). Pathway analyses also revealed a repression
of the PI3K-AKT pathway in miR-191/425 over-expressing cells.
Western blot analyses against pERK1/2, pAKT and its direct
targets pGSK3b confirmed the inhibition of PI3K-AKT signaling
and highlighted that miR-191 is primarily responsible for the
inhibition (Figure 5D). Moreover, we performed silencing of
SATB1, CCND2 and FSCN1 in order to evaluate the specific
contribution of each target to modulated miR-191/425 pathways.
We found that only SATB1 knockdown, as well as miR-191 over-
expression, were responsible for the up-modulation of b-catenin,
whereas both CCND2 and FSCN1 silencing decreased b-catenin
expression (Figure 5F). Finally, we found that SATB1 and
CCND2 silencing controlled AKT pathway activation
(Figure 5F). Taken together, these data indicate that miR-191/
425 modify a number of genes that play critical roles in controlling
the progression of highly invasive breast cancer.
miR191/425 cluster impairs tumorigenicity and
aggressiveness of breast cancer cells
Next, we assessed the in vitro biological effect of miR-191/425
on aggressive breast cancer cells. First, enforced expression of
miR-191 or miR-425 in MDA-MB-231 and MDA-MB-436 cells
induced an approximately 50% reduction in cell proliferation
(Figure 6A and Figure S12A). Lentivirally-infected cells over-
expressing either miR-191 or miR-425 were generated (Figure
S12B), and cell proliferation was assessed using a (2D) colony
formation assay (Figure 6B and Figure S12C). Cells over-
expressing miR-191 not only showed a reduced number of
colonies compared to control but also developed smaller colonies
than control (Figure 6B and Figure S12D); in contrast, miR-425-
expressing cells exhibited mainly a reduction in the number of
colonies (Figure 6B and Figure S12D). Further, we tested the
abilities of lentivirally-infected MDA-MB-231 cells to form
colonies in soft agar. Compared to control cells, cells over-
expressing either miR-191 or miR-425 formed significantly fewer
colonies, indicating a decrease in anchorage-independent growth
(Figure S12E). We then performed proliferation assays with cells
cultured in three dimensions (3D) within Matrigel, and we
observed that over-expression of either miR-191 or miR-425
impaired the formation of large filopodia/invadopodia-like struc-
tures at the periphery of the aggregates like in the control cells,
thus resulting in the appearance of tightly adherent aggregates
(Figure 6C). These results demonstrated that gain of cell adhesion
and reduced migration are related to the degree of miR-191 and
miR-425 expression in aggressive breast cancer cells. To more
accurately quantify the anti-proliferative properties of miR-191/
425 in aggressive breast cancer cells, flow cytometric analyses of
transiently-transfected cells revealed fewer cells in S phase and an
increased number of cells in G1 following over-expression of either
miR-191 or miR-425 compared to scrambled transfected cells
(Figure 6D and Figure S12F). To gain additional insight regarding
the numbers of cells arrested in G1, we treated the cells with the
microtubule-destabilizing agent nocodazole, which traps cycling
cells in M phase. Cell populations with enforced miR-191 or miR-
425 expression were characterized by significantly increased
numbers of cells remaining in G1 (Figure S12G), confirming that
both miRNAs caused cell-cycle arrest.
We next evaluated the in vivo effect of miR191/425 over-
expression on tumor growth. First, we tested if over-expression of
either miR-191 or miR-425 inhibits tumor growth of highly
aggressive MDA-MB-231 cells. Lenti-miR-191 and lenti-miR-
425 infected MDA-MB-231 were subcutaneously injected into
the right flank of athymic nude mice and the tumor growth was
monitored compared to control lenti-GFP infected and parental
MDA-MB-231 cells. Tumors in the parental and GFP control
groups were large, poorly differentiated, heavily necrotic and
highly vascularized that formed within only 22 days post-
implantation (5 out of 5 mice per group). In contrast, all five
mice injected with either miR-191- or miR-425-infected cells
exhibited greatly reduced tumor growth (Figure 6E). Interesting-
ly, miR-191 and miR-425 over-expressing tumors were strictly
non-invasive, as shown by their circumscribed profiles and
confinement within dense fibrotic capsules (Figure 6F), in stark
contrast to the spindle-like morphology of the parental and
control tumors along with islands of cancer cells invading the fat
pad and the muscle (Figure 6F and Figure S13A). Hence, ectopic
expression of miR-191 and miR-425 in MDA-MB-231 cells
impaired tumor growth and invasion in the surrounding tissue.
To determine whether miR-191 and miR-425 expression in the
primary tumors affects cell proliferation, we performed immu-
nohistochemistry for the proliferation marker Ki-67. We found
that the total number of Ki-67 positive cells in the tumors over-
expressing miR-191 or miR-425 were significantly lower relative
to the number observed in the control tumors (lenti-GFP control
cells: 97.3%; lenti-miR-191: 81%; lenti-miR-425: 89%; p-
value,0.05) (Figure 6F). High expression of miR-191 and miR-
425 in the tumor cells was confirmed by qRT-PCR (Figure
S13B). qRT-PCR revealed that miR-191 induced a reduction of
mesenchymal (fibronectin) and acquisition of epithelial (e-
cadherin and b-catenin) markers while miR-425 only a specific
increase in e-cadherin (Figure S13C). Reduction of SATB1,
CCND2 by miR-191 and FSCN1 by miR-425 over-expressing
tumors was confirmed by western blot analyses (Figure 6G; and
Figure S13D). Based on these numerous observations, we
concluded that the impaired tumor growth of miR-191- or
miR-425-over-expressing cells was a consequence of the reduced
cell proliferation.
We then assessed the effects of miR-191/425 over-expression on
migration and metastasis by using in vitro and in vivo experimental
approaches. First, we evaluated the rate of cell migration by using
the Boyden Chamber assay and found that miR-191- and miR-
425-transfected cells migrated more slowly than control MDA-
MB-231 cells (miR-191: p-value,0.05, ,3-fold; miR-425: p-
value,0.05, ,6-fold) (Figure 7A). Further, we performed wound-
healing assays on lenti-miR-191, lenti-miR-425 cells and GFP
control (Figure 7B). By 16 hour post wounding, parental cells and
repressed genes. (C) Luciferase activity was measured 24 h after transfection of HEK293 cells with reporter plasmids in which miR-binding sites listed
in Figure S8 were fused downstream the firefly luciferase gene. Reporter plasmids were transfected either with miR-191 or miR-425 and miR-negative
control (SCR). All graphs showed p-values,0.001 obtained with two-sided Student’s t-test. (D) miR-191/425 modulated proteins were analyzed by
western blot analyses 72 h after miR-191 and miR-425 over-expression in MDA-MB-231. (E) Increased of b-catenin protein levels in the cytoplasmic
fraction of miR-191/425 transfected MDA-MB-231. Immunoblots show the protein level of b-catenin in the nuclear and cytoplasmic fraction, whereas
DROSHA and GAPDH were used as loading controls for the nuclear and cytoplasmic proteins, respectively. Densitometric analyses of b-catenin
protein levels are shown. * represent p-value,0.01. (F) Modulation of pAKT, b-catenin after SATB1, CCND2, FSCN1 silencing. Vinculin is used as a
loading control. All error bars indicate s.d.
doi:10.1371/journal.pgen.1003311.g005
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GFP control cells migrated into the wound, resulting in 90% and
70% closure, respectively. In contrast, wound closure was
significantly less in miR-191 and highly impaired in miR-425
(miR-191: 60% closed; miR-425: 25% closed) (Figure 7B).
Migration and wound healing experiments were also performed
using MDA-MB-436 cells, and the results were essentially similar
(Figure S14A and S14B).
Finally, we tested the differential migratory abilities of miR-191
or 425-over-expressing cells by using an in vivo metastasis assay.
Control lenti-GFP, lenti-miR-191, lenti-miR-425 infected-cells
(2610‘6 cells) were injected into the lateral tail vein of 6-week-old
NOD-SCID mice, and their survival was evaluated in circulation,
extravasation to and growth in lungs. After 8 weeks, histological
analyses revealed that the number of micrometastasis was
markedly reduced in the lungs of mice injected with miR-191 or
miR-425 cells compared to the control tumor cells (Figure 7C). Of
note, we also observed pneumonitis only in mice injected with the
control GFP cells (Figure 7C). Collectively, all these data support
the idea that sustained miR-191 and miR-425 activity impairs
local invasion and metastatic colonization of breast cancer cells.
Figure 6. miR-191/425 cluster impairs tumorigenicity of aggressive breast cancer cells. (A) MTT assay in miR-191, miR-425 and scrambled
(SCR) control transfected MDA-MB-231 cells (* and ** indicate p-value,0.05 and 0.01, respectively). Microscopic photos of representative miR
transfected MDA-MB-231 cells (46magnification). (B) 2D colony formation assay in miR-191, miR-425, or empty vector control (GFP) lentivirally-
infected MDA-MB-231 cells. Representative micrograph of crystal violet-stained colonies. (C) Fluorescent (left) and bright field (right) images of miR-
191, miR-425, or empty vector control (GFP) lentivirally-infected MDA-MB-231 cells grown in Matrigel for 5 days. Bars, 100 mm. (D) Cell cycle analyses
of miR-191, miR-425 and scrambled control (SCR) transfected MDA-MB-231 cells. Cells were harvested 72 h following transfection, fixed, stained with
propidium iodide, and analyzed by flow cytometry; the data are representative of three independent experiments. (E) In vivo growth kinetics of
parental MDA-MB-231 cells compared to miR-191, miR-425, or empty vector control (GFP) lentivirally-infected cells. Images show average-sized
tumors for each group. The p-values were calculated on two different experiments performed with 5 mice per group. (F) Hematoxylin-eosin (H&E,
upper and middle rows) and Ki67 staining of xenograft tumors at 7 weeks after subcutaneous transplantation of miR-191, miR-425, or empty vector
control (GFP) lentivirally infected-MDA-MB-231 cells. Arrows in panels indicate areas of fat invasion, while asterisks identify the fibrous capsule. (G)
Levels of CCND2, SATB1, FSCN1 and fibronectin were measured by western blot analyses in 5 tumors of each experimental group. Vinculin was used
as a loading control.
doi:10.1371/journal.pgen.1003311.g006
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Discussion
Defining the role of the differentially regulated miRNAs in
breast cancer could lead to the development of new diagnostic
tools and therapeutic approaches. In the present study, we provide
new evidence for the role of miR-191 and miR-425 in breast
cancer. We demonstrate that expression of miR-191 and miR-425
occurs as a part of the same transcriptional unit and strongly
correlates with cellular ERa status. Moreover, we show that ERa
directly regulates the expression of miR-191 and miR-425. Finally,
our functional studies demonstrate that miR-191/425 cluster
exerts a dual role in breast cancer cells depending on their ERa
status: in ERa positive cells miR-191/425 work as oncogenes by
inducing proliferation in part through the suppression of EGR1
during the E2 stimulation; in ERa negative cells, they impair
tumor growth and invasiveness conferring a more epithelial
phenotype to highly aggressive breast cancer cells.
We have demonstrated that miR-191 and miR-425 are co-
expressed (Figure S4B) and, at least in part, transcriptionally
dependent from the host gene DALRD3 in normal human tissues
(Figure S2A, S2B). The identification of two distinct promoter
regions responsible for the production of the two DALRD3
isoforms may allow the independent production of DALRD3 from
the miRNAs and thus explain the partial correlation between
miR-191/425 and DALRD3 found in some of the human tissues.
Furthermore, the existence of the dual promoter for DALRD3
may contribute to ‘‘fine-tuning’’ of the estrogen-dependent
regulation of miR-191/425 and DALRD3 gene transcription.
We demonstrate that while E2/ERa signaling induces an increase
in miR-191/425 expression ERa activation has a negative effect
on the expression of the host gene DALRD3 (Figure 2B, Figure
S5C and S5D, and Figure S6). qRT-PCR of the two different
alternative splicing variants of DALRD3 showed that both
variants are preferentially expressed in ERa positive cells and
both reduced during E2 stimulation (Figure S3B and Figure S5C).
These results highlight that E2 stimulation of the miR-191/425/
DALRD3 transcriptional unit is essentially related to the
production of miR-191 and miR-425. The reduction of the host
gene isoform 1 may be explained with the mechanism proposed by
Gromak et al. which showed that the cleavage of an intron can
affect alternative splicing if it occurs between an alternatively
spliced exon and its intronic regulatory elements [58]. Moreover, it
has been demonstrated that ERa directly interacts with Drosha to
modulate the processing of E2-regulated microRNAs [59]. In this
scenario, we can hypothesize that the recruitment of ERa at the
upstream promoter (Figure 2C) might improve the assembly of the
Microprocessor complex at miR-191/425 locus and increase the
cleavage of the intron for the production of the miRs, impairing
the processing of the pre-mRNA. We further show that the
increase of miR-191 and miR-425 upon E2 stimulation is
associated with gradual reduction of polII accumulation on the
downstream promoter (Figure 2C). Interestingly, this negative
effect on DALRD3 promoter 2 is independent by ERa (silencing
of ERa does not modify the downstream promoter activity), but is
still related to E2 treatment, based on the strong reduction of
promoter activity after E2 treatment (Figure 2E and Figure S6C).
Figure 7. The miR-191/425 cluster reduces migration and metastatic dissemination of breast cancer cells. (A) Representative pictures
taken at 106magnification of crystal-violet-stained parental (NT), miR-191, miR-425 and scrambled control transfected MDA-MB-231 cells migrated
through inserts 24 hrs after plating. Collected data from three separate experiments performed in triplicate are represented as number of cells per
field. Error bars indicate s.d. And * represent p-value,0.05. (B) In vitro wound-healing assay comparing the progressive extent of migration by miR-
191, miR-425, or empty vector control (GFP) lentivirally-infected MDA-MB-231 cells. The photomicrographs were taken at 106magnification; bar,
100 mm. The widths of wounds were measured on the microscopic photos at 0, 5 h, 9 h and 16 h after wounding. Changes in wound width were
converted to percentages to represent wound closure. Error bars indicate s.d. and p-values,0.05. (C) Lung colonization assays of MDA-MB-231 cells
after injection into the tail vein of NOD-SCID mice (4 mice per cell line, 26106 cells per mouse). Eight weeks after injection, lungs were analyzed for
the presence of micrometastatic nodules. Analyses were carried out on H&E-stained histological sections (5 sections per lung). Data are represented
as mean (bars) and s.d. (p-values,0.05). Representative pictures of metastases embedded in the lung parenchyma.
doi:10.1371/journal.pgen.1003311.g007
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Both genomic and non-genomic estrogen actions may contribute to
the regulation of miR-191/425-DALRD3 transcriptional unit
[60,61]: E2 treatment induces recruitment of ERa at the upstream
promoter to improve only the accumulation of miR-191/425 (i.e.,
genomic regulation/processing activity), while estrogen-mediated
effects, transmitted via enzymatic pathways or ion channels, induces
repression of the downstream promoter (non-genomic regulation).
Next, we focused on the functional role of miR-191 and miR-
425 in ERa signaling. Inhibition of miR-191 and miR-425
strikingly impairs cell proliferation and tumor formation in ERa
positive cells (Figure 3A, 3D). Moreover, miR-19/425 overex-
pression in hormone deprived ERa positive cells, which have low
levels of endogenous miR-191/425, reduces cell cycle arrest and
apoptosis (Figure 3C). In silico analyses, based on the endonu-
cleolytical activity of microRNAs, identify Early Growth Response
1 (EGR1) as a miR-191 target (Figure 3E, 3F and Figure S9A).
EGR1 is involved in the regulation of cell growth and
differentiation in response to signals, such as mitogens, growth
factors, and stress stimuli [62,63]. In most human tumors, such as
breast cancer, fibrosarcoma, and glioblastoma, EGR1 is described
to be a tumor suppressor gene [64–66]. In fact, re-expression of
EGR1 in human tumor cells inhibits neoplastic transformation
[63]. EGR1 represents also an important upstream gatekeeper of
the p53 tumor suppressor pathway and many p53 downstream
target genes, such as CDKN1A (p21), are dependent on EGR1
status. We demonstrate that during E2 stimulation, after an initial
increase, the levels of EGR1 are repressed (Figure 3G and Figure
S9B). Inhibition of miR-191 blocks the suppression of EGR1 and
induces high levels of CDKN1A (p21) (Figure 3G, 3H) explaining
at least in part the anti-proliferative activity of miR-191/425
cluster knockdown. However, the tumor-suppressive role of EGR1
seems to be tissue specific, because several studies implicated a
tumor growth-promoting role of EGR1 in prostate cancer
progression [67–69].
The loss of ERa expression causes tumor growth that is no
longer under estrogen control, which leads to greater cancer
aggressiveness and the failure of endocrine therapy. Therefore,
restoration of ERa protein expression or signaling in ERa negative
breast cancer cells represents an important key event to promote
apoptosis and differentiation of aggressive breast cancer. Since
miR-191 and miR-425 are players of the ERa signaling, we also
inquire their role in ERa negative breast cancer. To this aim, we
overexpressed both miRs in ERa negative cells and showed that
miR-191 and miR-425 markedly alters the transcriptome of
aggressive breast cancer cells, resulting in impaired tumor growth
and metastasis (Figure 4 and Figure 5). Mechanistically, the effects
of miR-191 and miR-425 on tumor growth and invasion require,
at least in part, the suppression of SATB1, CCND2 and FSCN1.
Specifically, miR-191-mediated SATB1 repression is associated
with gain of epithelial markers (e.g., such as e-cadherin), and loss
of mesenchymal markers (e.g., fibronectin and vimentin)
(Figure 5C and Figure 6D). The increase of e-cadherin levels,
mediated by miR-191/425, results in greater cell-cell adhesion,
reduced detachment of cells, and cytoplasmic localization of b-
catenin (Figure 5E). Mounting evidence indicates multiple
reciprocal interactions of e-cadherin and cytoplasmic b-catenin
with EMT-inducing transcriptional repressors to destabilize an
invasive mesenchymal phenotype of epithelial tumor cells.
Moreover, SATB1 and CCND2 repression by miR-191 are
related to the suppression of the PI3K/AKT pathway and the
corresponding reduced cell proliferation and tumor growth. We
have also identified FSCN1, which is responsible for the reduced
invasiveness and partial reversion to an epithelial morphology, as a
target of miR-425 (Figure 6C).
All together our experiments demonstrate a duality in the
biological role of miR-191/425 cluster in breast cancer: estrogen
dependent-high levels of miR-191/425 induce proliferation in
ERalpha positive cells by suppressing a strong tumor-suppressor
gene, such as EGR1; low levels of miR-191/425 cluster are
essential for the high expression of important modulators, such as
SATB1, CCND2 and FSCN1, which confer a proliferative
advantage to aggressive breast cancer cells.
Materials and Methods
Cell culture and tissue samples
Human breast cancer cell lines MCF10A, MCF10F, MCF7,
T47D, BT474, BT483, ZR-75-1, MDA-MB361, HBL-100,
SKBr3, MDA-MB-468, MDA-MB-453, BT549, MDA-MB-436,
MDA-MB-231 as well as the Human Embryonic Kidney cell line
HEK293, were purchased from the American Type Culture
Collection (ATCC) and grown in accordance with ATCC
recommendations. ERa, progesterone receptor (PGR) and
HER2 status were confirmed for all cell lines by Western blot
analyses. All transfections were carried out with Lipofectamine
2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. For hormone depletion experiments, MCF7 cells
were grown to 70% confluency in phenol red–free DMEM
supplemented with 5% charcoal–dextran-stripped FBS for 6 days
and collected every two days with the relative normal growth
control. For estradiol (E2) treatments (Sigma Aldrich), MCF7 cells
were hormone starved for 6 days and then treated with E2
(10 nM) at the indicated times. For Fulvestrant treatments, MCF7
cells were treated daily with fulvestrant (Sigma Aldrich) (100 nM)
and collected at the reported time points. The 44 breast tumor
tissue samples were provided from the Department of Pathology,
The Ohio State University. All human tissues were obtained
according to a protocol approved by the Ohio State Institutional
Review Board.
Taqman qRT–PCR and human microRNA card array
Quantitative real-time PCR (qRT-PCR) was performed with
the TaqMan PCR Kit (Applied Biosystems, Foster City, CA),
followed by the detection with the Applied Biosystems 7900HT
Sequence Detection System (P/N: 4329002, Applied Biosystems).
PCR was carried out in 10 mL of reaction buffer containing
0.67 mL RT product, 1 mL TaqMan Universal PCR Master Mix
(P/N: 4324018, Applied Biosystems), 0.2 mM TaqMan probe,
1.5 mM forward primer, and 0.7 mM reverse primer. The
reaction mixture was incubated in a 96-well plate at 95uC for
10 minutes, followed by 40 cycles of denaturation (95uC for
15 seconds) and extension (60uC for 1 minute). All reactions were
performed in triplicate. Simultaneous quantification of small
endogenous nucleolar RNA U44/U48 was used as a reference
for TaqMan assay data normalization. For quantification of
DALRD3, trefoil factor 1 (TFF1/pS2), pri-miR-191, pri-miR-425,
VEGFA, FSCN1, EGR1, TNC, CDC42, SATB1, SOX4,
CCND1, VIM, CCND2, E2F1, SIAH2, API5, FIBR, CSDA,
MYC, CTNN1 and CDH1 mRNAs, the appropriate TaqMan
probes were purchased from Applied Biosystems. The TaqMan
Array Human MicroRNA Card (Applied Biosystem) Set v3.0 is a
two-card set containing a total of 384 TaqMan MicroRNA Assays
per card that enables accurate quantification of 754 human
miRNAs. Included on each array are three TaqMan MicroRNA
Assays as endogenous controls to aid in data normalization and
one TaqMan MicroRNA Assay not related to human as a negative
control.
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Microarray analyses
The hybridized Human Genome U133A 2.0 Array (Affymetrix)
was scanned and analyzed with the Affymetrix Microarray
Analysis Suite version 5.0. The average density of hybridization
signals from three independent samples was used for data analysis,
and genes with signal density less than 300 pixels were omitted
from the analysis. P values were calculated with two-sided t-tests
with unequal variance assumptions. To correct for multiple
hypothesis testing, the false discovery rate was calculated.
Differentially expressed genes were selected using both a false
discovery rate of less than 0.01 and a fold-change greater than 1.5
or less than 21.5. A tree cluster was generated by hierarchical
cluster analysis to classify the miR-transfected cells; for this
analysis, we used average linkage metrics and centered Pearson
correlation (Cluster 3.0). Java Treeview 1.1 (http://sourceforge.
net/projects/jtreeview/) was used for tree visualization. The
associations between gene modulations by two miRNAs were
examined using a two-sided Fisher exact test. The association
between modulations by any two miRNAs was statistically
significant if P was less than .001. The online program Pathway-
Express (http://vortex.cs.wayne.edu/Projects.html) was used to
explore the most biologically relevant pathways affected by a list of
input genes. Specific biological pathways were defined by the
Kyoto Encyclopedia of Genes and Genomes database (Kanehisa
Laboratories, Kyoto, Japan) (http://www.genome.jp/kegg/
pathway.html). Pathways were considered statistically significant
if the corrected gamma P was less than 0.01.
Cell cycle analyses
For cell-cycle analysis, MDA-MB-231 and MDA-MB-436 cells
were plated in 6 cm dishes, transfected as indicated in the figures,
trypsinized, washed in PBS, and fixed with ice-cold 70% ethanol
while vortexing. Cells were rehydrated in PBS and stained 30 min
at RT with propidium iodide (50 mg/ml PI, 0.5 mg/ml RNase in
PBS) prior to flow-cytometric analysis. Lenti-GFP, lenti-191 and
lenti-425 infected-cells were also analyzed by flow cytometry after
12 h treatment with nocodazole.
In vivo experiments
All mouse experiments were conducted following protocols
approved by the institutional animal care and use committee at
the Ohio State University. Parental MDA-MB-231, lenti-GFP,
lenti-191 and lenti-425 infected-cells (56106) were injected subcu-
taneously into the right flank of 6-week-old athymic nude mice.
Tumor size was assessed twice per week using a digital caliper.
Tumor volumes were determined by measuring the length (l) and
the width (w) of the tumor and calculating the volume (V= lw2/2).
Statistical significance between the control and treated mice was
evaluated using Student’s t test. We sacrifiedthe mice 35 days after
injection and tumors were excided and processed for histology and
for RNA and protein extractions. 4 mm sections of tumor tissues
were stained with hematoxylin/eosin and with Ki-67 by immuno-
histochemistry. ForMCF7 and ZR-75-1 xenografts, estradiol pellets
(Innovative Research) were implanted in nude mouse and after two
weeks mice were injected subcutaneously with one 10 cm plate of
anti-miR191/425 transfected MCF7 or ZR-75-1 cells. Mouse
experiments were conducted after approval by the institutional
animal care and use committee at Ohio State University.
Migration assay
Transwell insert chambers with an 8-mm porous membrane
(Greiner Bio One) were used for the assay. Cells were washed
three times with PBS and added to the top chamber in serum-free
medium. The bottom chamber was filled with medium containing
10% FBS. Cells were incubated for 24 h at 37uC in a 5% CO2
humidified incubator. To quantify migrating cells, cells in the top
chamber were removed by using a cotton-tipped swab, and the
migrated cells were fixed in PBS, 25% glutaraldehyde and stained
with crystal violet stain, visualized under a phase-contrast
microscope and photographed. Crystal-violet–stained cells were
then solubilized in acetic acid and methanol (1:1), and absorbance
was measured at 595 nm. For the scratch assay, parental MDA-
MB-231 cells, lenti-GFP, lenti-miR191 and lenti-miR425 infected-
cells were plated in culture dishes and after 24 h the confluent
monolayer was scratched. Images were acquired directly after
scratching (0 h) and after 5 h, 9 h and 16 h. For quantification of
migration distance Image J software was used. The distance
covered was calculated by converting pixel to millimeters.
miRNA locked nucleic acid in situ hybridization
In situ hybridization (ISH) was carried out on deparaffinized
human breast tissues using previously published protocol (Nuovo
GJ, 2009), which includes a digestion in pepsin (1.3 mg/ml) for
30 minutes. The probes contained the dispersed locked nucleic
acid (LNA) modified bases with digoxigenin conjugated to the 59
end. The probe cocktail and tissue miRNA were co-denatured at
60uC for 5 minutes, followed by hybridization at 37uC overnight
and a stringency wash in 0.26SSC and 2% bovine serum albumin
at 4uC for 10 minutes. The probe-target complex was seen due to
the action of alkaline phosphatase on the chromogen nitroblue
tetrazolium and bromochloroindolyl phosphate (NBT/BCIP).
Negative controls included the use of a probe that should yield a
negative result in such tissues (scrambled miRNA).
RNA extraction and Northern blotting
Total RNA isolation was performed with Trizol (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. For,
acrylamide northern blotting 10 mg aliquots of total RNA were
resolved on a 15% denaturing polyacrylamide gel (Bio-Rad,
Hercules, CA) and were electrophoretically transferred to Bright-
Star blotting membrane (Ambion Inc, Austin, TX). The oligonu-
cleotide encoding the complementary sequence of the mature
miRNA annotated in the miRNA Registry (release 14: September
2009) was end-labeled with [c32 P]-ATP by T4 polynucleotide
kinase (USB, Cleveland, OH). RNA-blotted membrane was
prehybridized in Ultrahyb Oligo solution (Ambion Inc) and
subsequently hybridized in the same solution containing probe at a
concentration of 106 cpm/mL at 37uC overnight. The membrane
was washed at high stringency in the solution containing 26
standard saline citrate and 1% sodium dodecyl sulfate at 37uC.
Northern hybridization signals were captured and converted to
digital images with the Typhoon Scanner (GE Healthcare
Biosciences, Piscataway, NJ).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed
with the ChIP assay kit (Upstate Biotechnology, Lake Placid, NY)
with minor modifications. Briefly, MCF7 and MDA-MB-436 cells
were hormone starved for 6 days and then treated with E2
(10 nM) for 3 h, 6 h and 24 h. The cross-linking was performed
with 1% formaldehyde at 37uC for 10 minutes. Cells were then
rinsed with ice-cold PBS and resuspended in 0.4 mL of lysis buffer
containing 1% sodium dodecyl sulfate, 10 mM EDTA, 50 mM
Tris–HCl, pH 8.1, 16 protease inhibitor cocktail (Roche Molec-
ular Biochemicals), and sonicated. A 30 mL aliquot of the
preparation was treated to reverse the cross-linking, deproteinized
with proteinase K, extracted with phenol–chloroform, and the
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DNA concentration determined by Nanodrop 2000c (Thermo
Scientific, Wilmington, DE) measurements. An aliquot of chro-
matin preparation containing 25 mg DNA was used per ChIP. The
primary antibodies used for immunoprecipitation were rabbit
polyclonal ERa (Bethyl Laboratories [Montgomery, TX] A300-
498A), rabbit IgG control (Zymed, Carlsbad, CA), rabbit
polyclonal acetyl-H3 (Upstate Biotechnology), rabbit polyclonal
polIII (Upstate Biotechnology). ChIP-enriched DNA was subject-
ed to SYBR green qPCR (Applied Biosystems). Primer sequences
are listed in the Primer Table. Results were expressed as relative
enrichment according to the following formula: 22[(ctChIP2ctin-
put)2(ctIgG2ctinput)], where ctChIP, ctIgG, and ctinput indicate the cycle
threshold for the specific antibody, IgG control, and input (5% of
the total amount of immunoprecipitated material), respectively.
Transcriptional elements analyses
For miR-191 and -425 promoter prediction, a 9200 base pair
(bp) DNA genomic region spanning miR-191 and-425 was used as
input for the online software Promoter 2.0 (http://www.cbs.dtu.
dk/services/promoter/).
Plasmid construction
To generate SATB1, CCN2, CTDSP2, SOX4, LRCC8A,
SLC16A2, EGR1, CSDA, FSCN1, TNC, SIAH2 and CSDA
luciferase reporter constructs, the 39UTRs were amplified by
polymerase chain reaction (PCR) and cloned downstream of the
luciferase-coding sequence in the pGL3-control vector at the XbaI
restriction site (Promega).Mutations were introduced into themiRNA-
binding sites by using the QuikChange Mutagenesis Kit (Stratagene,
La Jolla, CA). To map the miR-191-425 promoter, prom1 or prom2
genomic region (see schematic representation of miR-191/425-
DARLD3 transcription unit, Figure 3, C) were amplified by PCR
and cloned at the NheI and XhoI sites of the pGL3-basic vector
(Promega). All constructs were sequenced to verify integrity.
Luciferase assay for target and promoter identification
To confirm that SATB1, CCN2, CTDSP2, SOX4, LRCC8A,
SLC16A2, EGR1, CSDA, FSCN1, TNC, SIAH2, CSDA harbor
responsive seed regions (complementary sequences) so that miR-
191 and/or miR-425 can bind to their 39UTRs, 250 ng of pGL3
reporter vector carrying the miR-191 or miR-425 binding site (see
plasmid construct, Figure S9A), 25 ng of the phRL-SV40 control
vector (Promega), and 100 nM miRNA precursors or scrambled
sequence miRNA control (Ambion, Inc, Austin, TX) were
cotransfected into HEK293 cells in 24-well plates. To map the
miR-191 and miR-425 promoter, 250 ng of pGL3 reporter vector
carrying prom1 or prom2 genomic region (see schematic
representation of miR-191/425-DARLD3 transcription unit,
Figure 3, C) and 25 ng of the phRL-SV40 control vector were
cotransfected into HEK293 cells in 24-well plates. To asses
estrogen responsiveness of the two promoter regions, same
experiment was carried out in 5 breast cancer cell lines with
different ERalpha status, in MCF7 cells after E2 (10 nM)
treatment and in MCF7 after ERalpha silencing. Firefly luciferase
activity was measured with a Dual Luciferase Assay Kit (Promega)
24 hours after transfection and normalized with a Renilla
luciferase reference plasmid. Reporter assays were carried out in
quadruplicate. Statistical significance was analyzed by the
unpaired Student t test.
Western blotting
All cell lysates were prepared by using RadioImmuno Precip-
itation Assay Buffer (Pierce, Rockford, IL). Fifty micrograms of cell
lysates was separated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and then electroblotted onto a polyvinylidene
fluoride membrane (Hybond P; Amersham Biosciences, Piscat-
away, NJ). All primary antibodies used for western blot analyses
are reported in Supplemental Materials and Methods (available
online). Detection was performed with horseradish peroxidase–
conjugated secondary antibodies (specific to rabbit and mouse) and
enhanced chemiluminescence (Pierce).
Nuclear/cytoplasmic differential protein extraction
Nuclear/Cytoplasmic differential protein extraction was per-
formed by using the NE-PER Nuclear and Cytoplasmic extraction
kit (Pierce) according to the manufacturer’s instructions.
Generation of stable clones with miR-191 and miR-425
overexpression
MDA-MB-231 cells were stably infected with the Human pre-
microRNA Expression Construct Lenti-miR expression plasmid
containing the full-length miR-191 or miR-425 and the GFP gene
under the control of two different promoters (System Biosciences).
An empty vector was used as control. Pre-miRs expression and
control constructs were packaged with pPACKH1 Lentivector
Packaging Plasmid mix (System Biosciences) in a 293TN
packaging cell line. Viruses were concentrated using PEGit Virus
Precipitation Solution, and titers were analyzed using the
UltraRapid Lentiviral Titer Kit (System Biosciences). Infected
cells were selected by FACS analysis (FACScalibur; BD Biosci-
ence). Infection efficiency .90% was verified by fluorescent
microscopy and confirmed by real-time PCR for miRs expression.
Proliferation assays
MDA-MB-231 cells, previously transfected with miR-191 or
miR-425 precursors for 72 h, were plated (3000 per well) in 96-
well plates and grown for 96 hours after transfection (final miRNA
concentration of 100 nM) in normal culture conditions. MCF7 in
normal culture conditions (+E2) transfected with anti-miR-191/
425 and CTR oligonucleotide or in hormon deprivation
conditions (2E2) transfected with miR-191/425 and CTR
oligonucleotide were plated in 96-well plates and grown for
96 hours after transfection. Cell proliferation was documented
every 24 hours for 4 days using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay kit (Promega, Madison, WI),
and absorbance at 490 nm was evaluated by a SpectraMax 190
microplate reader (Molecular Devices, Sunnyvale, CA).
Supporting Information
Figure S1 miR-191/425 genomic locus. Schematic representa-
tion of the human (A) and murine (B) genomic locus of miR-191/
425 cluster. miRNAs are represented with red lines. Green boxes
represent the CpG islands. Arrowheads indicate the direction of
the transcription.
(TIF)
Figure S2 Co-expression of miR-191 and miR-425 with their
host gene, DALRD3, in normal tissues and breast cancer cells. (A)
Quantitative RT-PCR on mature miR-191, miR-425 and
DALRD3 mRNA levels in 20 normal human tissues. (B) XY
scatter plots to define the correlation between miR-191/425/
DALRD3 expression in human normal tissues. (C) Expression
levels of miR-191 and miR-425 in human breast cancer cells by
qRT-PCR. All error bars indicate s.d.
(TIF)
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Figure S3 Expression of DALRD3 mRNA in breast cancer
specimens and cancer cells. (A) DALRD3 transcript expression
with different probes in breast tumor subtypes from Oncomine
analysis. The first author and statistical significance are indicated.
(B) SYBR qRT-PCR to discriminate the expression levels of the
two main splicing variants of DALRD3 in 15 breast cancer cells.
Isoform1 represents the splicing variants that may be responsible
for the transcription of miR-191/425 cluster.
(TIF)
Figure S4 miR-191 and miR-425 in situ hybridization (ISH) in
human breast cancer. (A) In situ hybridization analysis of miR-191
and miR-425 expression in breast cancer tissues with different
ERa expression status. Bars represent 200 mm. Two different
cores for each microRNA and scrambled control oligonucleotide
are represented for each category. Results are reported in the table
as a percentage of the total number of ERa positive and ERa
negative cores. (B) Co-labeling for miR-191 and miR-425 in
human ERa positive breast tissue. Large and small arrows indicate
tumor and stroma cells, respectively.
(TIF)
Figure S5 miR-191/425 and estrogen regulation. (A) qRT-PCR
on TFF1/pS2 and mature miR-17 upon E2 (10 nM) stimulation.
MCF7 cells were hormone starved for 6 days and treated daily
with estrogen for 72 h. (B) qRT-PCR on the primary precursor of
mir-191 and miR-425 after E2 (10 nM) stimulation. (C) qRT-PCR
for both splicing variant1 ad 2 of DALRD3 after hormone
stimulation of MCF7 cells. (D) qRT-PCR for total DALRD3,
splicing variants1 and 2, and TFF1/pS2 after hormone starvation
of MCF7 cells (NT: untreated; HS: hormone starved). Error bars
indicate s.d. and * represent p-value,0.05 obtained with two-
sided Student’s t-test.
(TIF)
Figure S6 Fulvestrant treatment reduces miR191/425 levels.
ERa positive cells, MCF7, were treated daily with fulvestrant
(100 nM) and collected at the reported time point. (A) Western
blot analyses to control ERa degradation after 72 h of fulvestrant
treatment. GAPDH levels were used as a loading control. (B) miR-
191/425 levels were assessed after 72 h of fulvestrant treatment by
qRT-PCR. (C) qRT-PCR was used to define the levels of
DALRD3 and TFF1/pS2 expression during fulvestrant treatment.
Error bars indicate s.d. and * represents p-value,0.001 obtained
with two-sided Student’s t-test.
(TIF)
Figure S7 miR-191/425-DALRD3 promoter identification. (A)
In silico analyses (http://www.cbs.dtu.dk/services/Promoter/) for
the identification of the promoter elements related to miR-191/
425-DALRD3 genomic DNA sequence. Outputs are reported in
the table and represent the prediction for a transcription start site
occurring within 100 base pairs upstream from that position. (B)
Luciferase assay for prom1 and prom2 luciferase plasmids in 5
breast cancer cells with different ERa status. (C) Luciferase assay
for prom1 and prom2 luciferase plasmids in ERa positive MCF7
cells after silencing of ERa. MCF7 were transfected with siRNA
against ERa and scrambled siRNA control (100 nM). 48 h after
transfection cells were transfected again with prom1 and prom2
plasmids and luciferase experiments were carried out 24 h after.
Results for the luciferase assay are presented as an average of three
independent experiments: error bars indicate s.d. and * represents
p-value,0.001 obtained with two-sided Student’s t-test.
(TIF)
Figure S8 miR-191/425 proliferative effect in ERa positive
breast cancer cells. (A) Cell cycle analyses of ZR-75-1 cells
transfected with anti miR-191/425 and scrambled control (CTR)
oligonucleotide in normal culture condition. Cells were harvested
72 h following transfection, fixed, stained with propidium iodide,
and analyzed by flow cytometry; the data are representative of
three independent experiments. (B) In vivo growth kinetic of ZR-
75-1 cells transfected with anti-miR-191/425 and scrambled
control oligonucleotide. Briefly, ZR-75-1 were transfected in
10 cm plates by using 2-O-methyl anti miR-191 and miR-425
oligonucleotides (100 nM); 48 h after transfection, cells were
detached and injected in nude mice previously implanted (two
weeks before injection) with estradiol pellets. Images show
average-sized tumors for each group. p-value was calculated on
one experiment performed with 5 mice for each group.
(TIF)
Figure S9 E2 modulated targets of miR-191 and miR-425. (A)
Intersection of predicted miR-191, miR-425 human targets and
E2 repressed genes in MCF7 and ZR-75-1 cells. Only commonly
modulated target genes are reported in the gray boxes. (B) qRT-
PCR for EGR1 mRNA after E2 stimulation in MCF7 cells. Gene
expression levels are reported as relative expression to GAPDH
levels. Error bars indicate s.d. * represent p-value of 0.05. (C)
qRT-PCR for miR-191 after E2 stimulation in anti-miR191 and
scrambled control oligonucleotide transfected MCF7 cells. Gene
expression levels are reported as relative expression to GAPDH
levels. Error bars indicate s.d.
(TIF)
Figure S10 miR-191 and miR-425 signature in aggressive breast
cancer cells. miR-191, miR-425 and scrambled control were
transfected in MDA-MB-231 and cells were collected 72 h after
transfection for genome-wide expression analyses. Differentially
expressed genes (fold change .1.2 and p-value,0.001) are
represented in the hierarchical tree and the modulated biological
pathways are enlisted based on the Impact factor strength of miR-
activated (blue) and repressed (yellow) genes.
(TIF)
Figure S11 Representation of miR191/425 binding sites of the
target genes. (A) Schematic representation of miR191 and miR425
binding sites located in the 39UTR (in green) of the target genes.
The blue line defines the 39UTR fragment cloned into pGL3
control plasmid and the arrowhead indicates the position of the
miRNA binding site, whose sequence is reported below with the
mutagenesis strategy used to generate the disruption between
miRNA and mRNA of the target gene. (B) Luciferase assays for
wildtype and disrupted miRNA binding sites of all target genes
with increased luciferase activity after miR191 or miR425
enforced expression on mutated plasmid. Luciferase activity values
for wildtype and mutated plasmids are represented as a ratio
between the relative luciferase activity of miR-transfected cells
with the relative luciferase activity of control-transfected cells.
(TIF)
Figure S12 miR-191/425 impair tumorigenicity of aggressive
breast cancer cells. (A) MTT assay revealed a reduced growth rate
in miR-191 and miR-425 overexpressing MDA-MB-436 cells
compared to scrambled control cells. Error bars indicate s.d. and
asterisks indicate p-value,0.05. (B) qRT-PCR to verify miR-191
and miR-425 overexpression in lenti-infected MDA-MB-231 or
MDA-MB-436. Error bars indicate s.d. (C,D) 2D colonies
formation assay in MDA-MB-436 stable cell line expressing
miR-191 or miR-425 from lentiviral expression vectors, compared
to the corresponding GFP control cells. Colony counting was
performed by using the GS-800TM calibrated densitometer. Error
bars indicate s.d. and asterisks indicate p-value,0.05. (E) Soft agar
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assay in which cells were seeded at a density of 46103 cells per 35-
mm dish and cultured in 0.35% soft agar in RPMI 10% FBS at
37uC for 21 days. Colonies were stained with 0.05% crystal violet.
Colony numbers in the entire dish were counted by using the GS-
800 calibrated densitometer. Error bars indicate s.d. and asterisks
indicate p-value,0.05. (F) Cell cycle analyses of MDA-MB-436
transiently-transfected cells. Cells were harvested 72 h following
transfection, fixed, stained with propidium iodide and analyzed by
flow cytometry. The data obtained were analyzed using ModFit
software. Cells in G1 and in G2 phase of cell cycle are reported in
red, cells in S phase are indicated with white and blue bars. Flow
cytometry plots are representative of three independent experi-
ments. (G) Lenti-viral infected MDA-MB-231 were analyzed by
propidium iodide staining after 100 ng/mL nocodazole treatments
for 16 h, before cells were released and harvested for FACS
analysis. The data obtained were analyzed using ModFit software.
Cells in G1 and in G2 phase of cell cycle are reported in red, cells
in S phase are indicated with white and blue bars. Flow cytometry
plots are representative of three independent experiments. (H)
miR-191/425 modulated targets were analyzed by Western blot
analyses 72 h after miR-191 and miR-425 overexpression in
MDA-MB-436. Representative Western blots are shown.
(TIF)
Figure S13 miR-191/425 in vivo effects. (A) Hematoxylin-eosin
of subcutaneous MDA-MB-231 lentiGFP-infected tumors. Arrows
in panels indicate areas of tumor invasion in the muscle cells of the
fibrotic capsule. (B) qRT-PCR to verify the expression of miR-191
and miR-425 in the resected xenografted tumors. (C) Expression
levels of fibronectin, e-cadherin and beta-catenin were determined
by taqman qRT-PCR in xenografted tumors. Error bars indicate
s.d. (* indicates p-value,0.01; ** indicates p-value = 0.011). (D)
Densitometric analyses of the Western blots presented in
Figure 5H.
(TIF)
Figure S14 miR-191/425 impair motility of MDA-MB-436
breast cancer cells. (A) Transwell motility assay was performed by
plating miR191,-425 and scrambled control transfected MDA-
MB-436 cells on inserts. Collected data from three separate
experiments performed in triplicate are represented as number of
cells per field. (B) Wound healing assay done on the miR-191,-425
stable clones and GPF control cells MDA-MB-436. The diameters
of wounds were measured on the microscopic photos at 0, 5 h, 9 h
and 16 h after wounding. Changes in wound diameter were
computed into percentage to represent wound closure. Error bars
indicate s.d.
(TIF)
Table S1 microRNA differentially expressed after hormone
starvation and estradiol stimulation. Taqman multiplex miRNA
cards results of hormone starvation and E2 stimulation of MCF7
cells. All microRNAs represented have a p-value,0.05 and a fold
change .1.2.
(XLS)
Table S2 Gene expression signature of miR-191 and miR-425
in MDA-MB-231 cells. All modulates genes with a fold change
and p-value higher of 1.5 and 0.05 were reported. Modulated
targets were obtained by comparison between miR-down-
modulated gene list and Tagetscan predicted targets.
(XLS)
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